INmune Bio (NASDAQ:INMB) Trading 4.5% Higher – What’s Next?

Shares of INmune Bio, Inc. (NASDAQ:INMB) were up 4.5% during mid-day trading on Tuesday . The company traded as high as $1.85 and last traded at $1.74. 1,792,150 shares were traded during mid-day trading, an increase of 56% from the average session volume of 1,145,731 shares. The stock had previously closed at $1.6650.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INmune Bio in a research note on Thursday, June 11th. Finally, Wall Street Zen downgraded INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

INmune Bio Stock Performance

The firm has a market cap of $46.25 million, a price-to-earnings ratio of -1.04 and a beta of 0.97. The stock’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $1.44.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04.

Institutional Trading of INmune Bio

Several hedge funds and other institutional investors have recently bought and sold shares of INMB. Quadrature Capital Ltd acquired a new stake in shares of INmune Bio during the 4th quarter worth approximately $26,000. Intech Investment Management LLC acquired a new position in INmune Bio during the second quarter worth $26,000. Squarepoint Ops LLC purchased a new position in INmune Bio in the 3rd quarter valued at about $30,000. Virtu Financial LLC purchased a new position in shares of INmune Bio in the fourth quarter valued at approximately $32,000. Finally, Wells Fargo & Company MN boosted its stake in INmune Bio by 79.0% during the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after purchasing an additional 10,970 shares during the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.